Skip to main content
. 2018 Nov 5;128(12):5479–5488. doi: 10.1172/JCI120156

Figure 5. AZD9150 treatment leads to enhanced differentiation from primary MDS stem and progenitor cells.

Figure 5

AZD9150 treatment leads to enhanced differentiation from primary MDS stem and progenitor cells. (A) Clonogenic assays from primary MDS mononuclear cell samples (n = 10) were performed, and cells were harvested after 14 days and assessed for differentiation by flow cytometry. An increase in erythroid (glycophorin A) and myeloid (CD11b) differentiation was seen in samples compared with controls. (B) A representative flow plot shows increased erythroid differentiation with an increase in the proerythroblasts and basophilic erythroblasts after AZD9150 treatment (10 μM). (C) The drug-treated colonies were also larger in size at the same magnification. Original magnification, 10×.